Figure 7
Complete response to JCXH-211 in immune checkpoint inhibitor-sensitive EMT6 breast cancer in an orthotopic tumor model. (A–I) At day 7 after EMT6 tumor implantation in mammary fat pad, tumor-bearing mice (average tumor volume, 90 mm3) were treated PBS control (vehicle), anti-PD1 antibody (5 mg/kg, intraperitoneal, eight times, 3–4 day interval), JCXH-211m (0.1, 1, or 10 μg, intravenous, three times, at 14 day interval), or combination of JCXH-211m and anti-PD1 antibody (n = 8, each group). (A–H) The tumor volumes of individual mice in the group of indicated treatment regimen were plotted. Number of mice with complete response per total number of mice treated is indicated above the x-axis. (I) Survival was plotted using the Kaplan–Meier curve and analyzed using the log-rank test. *P < 0.05; **P < 0.01; ***P < 0.001; ns not significant. (J) At 44 days after tumor implantation, indicated numbers of mice from JCXH-211m-treated groups in (A–I, Supplementary Fig. 6B) showed complete tumor regression and were rechallenged with the same EMT6 tumors on contralateral side. No additional treatment was given after tumor rechallenge. The tumor volumes of individual mice were plotted. See also Supplementary Fig. 6.
